FDA approves muscle-targeted treatment ISEMBYLD for SMA

Scholar Rock receives FDA approval for ISEMBYLD, the first muscle-targeted therapy for SMA patients receiving SMN2-targeted treatments, with the product rollout already underway. The approval is marked by positive clinical endpoints on motor function improvement, garnering significant market interest for the biotechnology company.